▎药明康德内容团队编辑艾伯维（AbbVie）公司今日宣布，美国FDA已批准该公司与辉瑞（Pfizer）联合开发的Emblaveo（aztreonam和avibactam）上市，与甲硝唑联合使用，治疗18岁及以上复杂性腹腔内感染（cIAI）患者，包括由 ...

Aztreonam–avibactam is a promising treatment for complicated intra-abdominal infections and hospital-acquired or ...

AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...

EMBLAVEO与甲硝唑联合使用，针对特定革兰氏阴性细菌引起的感染，包括大肠杆菌和肺炎克雷伯菌等。该批准基于该药物有限的临床安全性和有效性数据，解决了抗菌素耐药性（AMR）防控的关键需求。如果不加以解决，AMR可能在2050年前导致全球超过3,900万人死亡。凭借70.4%的强劲毛利率和稳健的现金流，AbbVie有能力支持这一重要治疗方案的商业化。投资者可通过 InvestingPro ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

AbbVie (NYSE:ABBV) said it has received FDA approval for its intravenous antibiotic treatment Emblaveo. The FDA approved Emblaveo, a combination of aztreonam and avibactam, for use in combination with ...

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

University of Detroit Mercy's College of Health Professions is offering online information sessions for students interested in three graduate programs in fast-growing nursing ...

Power to the Patients (PTTP) and Jon "Bones" Jones released a new PSA that will air during the Big Game. The PSA release follows yesterday's announcement of PTTP's new partnership with the UFC ...